Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Regulation FD Disclosure

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

Bellerophon Therapeutics, Inc. (the Company) issued a press
release on May 1, 2017 announcing data showing that INOpulse was
associated with clinically meaningful improvements in
hemodynamics and exercise capacity in patients with pulmonary
hypertension associated with idiopathic pulmonary fibrosis, or
PH-IPF. A copy of this press release is attached hereto as
Exhibit 99.1. The information included in Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release dated May 1, 2017 (furnished and not
filed for purposes of Item 7.01)


About Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Recent Trading Information

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) closed its last trading session 00.00 at 1.45 with 425,287 shares trading hands.

An ad to help with our costs